Identification and Characterization of a Novel Gene Rearrangement in an Advanced Colorectal Cancer Patient: A Case Report

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Dec 17

PMID 39684377

Authors

Juan Carlos Montero

Raquel Tur

Andrea Jimenez-Perez

Elena Filipovich

Susana Alcaraz

Marta Rodriguez

Mar Abad

Jose Maria Sayagues

Affiliations

Soon will be listed here.

Abstract

Despite the existence of effective therapy options for patients with localized colorectal cancer, advanced-stage patients have limited therapies. Genomic profiling is a promising tool for guiding treatment selection as well as patient monitoring. Here, we describe a novel gene rearrangement () detected in a patient with advanced colorectal cancer that could be a therapeutic target. The patient underwent surgical resection but died after the operation from fecal peritonitis. To our knowledge, this is the first report in which the gene rearrangement has been described in an advanced colorectal adenocarcinoma patient.

References

Pietrantonio F, Di Nicolantonio F, Schrock A, Lee J, Morano F, Fuca G . RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. Ann Oncol. 2018; 29(6):1394-1401. DOI: 10.1093/annonc/mdy090. View

Jinesh G, Sambandam V, Vijayaraghavan S, Balaji K, Mukherjee S . Molecular genetics and cellular events of K-Ras-driven tumorigenesis. Oncogene. 2017; 37(7):839-846. PMC: 5817384. DOI: 10.1038/onc.2017.377. View

Merolla F, Luise C, Muller M, Pacelli R, Fusco A, Celetti A . Loss of CCDC6, the first identified RET partner gene, affects pH2AX S139 levels and accelerates mitotic entry upon DNA damage. PLoS One. 2012; 7(5):e36177. PMC: 3360053. DOI: 10.1371/journal.pone.0036177. View

Mulkidjan R, Saitova E, Preobrazhenskaya E, Asadulaeva K, Bubnov M, Otradnova E . , , and Gene Fusions in Colorectal and Non-Colorectal Microsatellite-Unstable Cancers. Int J Mol Sci. 2023; 24(17). PMC: 10488195. DOI: 10.3390/ijms241713610. View

Grieco M, Santoro M, Berlingieri M, Melillo R, Donghi R, Bongarzone I . PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell. 1990; 60(4):557-63. DOI: 10.1016/0092-8674(90)90659-3. View

Morra F, Merolla F, DAbbiero D, Ilardi G, Campione S, Monaco R . Analysis of CCDC6 as a novel biomarker for the clinical use of PARP1 inhibitors in malignant pleural mesothelioma. Lung Cancer. 2019; 135:56-65. DOI: 10.1016/j.lungcan.2019.07.011. View

Siegel R, Miller K, Wagle N, Jemal A . Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1):17-48. DOI: 10.3322/caac.21763. View

Le Rolle A, Klempner S, Garrett C, Seery T, Sanford E, Balasubramanian S . Identification and characterization of RET fusions in advanced colorectal cancer. Oncotarget. 2015; 6(30):28929-37. PMC: 4745701. DOI: 10.18632/oncotarget.4325. View

Celetti A, Cerrato A, Merolla F, Vitagliano D, Vecchio G, Grieco M . H4(D10S170), a gene frequently rearranged with RET in papillary thyroid carcinomas: functional characterization. Oncogene. 2004; 23(1):109-21. DOI: 10.1038/sj.onc.1206981. View

10.

Morra F, Luise C, Merolla F, Poser I, Visconti R, Ilardi G . FBXW7 and USP7 regulate CCDC6 turnover during the cell cycle and affect cancer drugs susceptibility in NSCLC. Oncotarget. 2015; 6(14):12697-709. PMC: 4494967. DOI: 10.18632/oncotarget.3708. View

11.

Visconti R, Della Monica R, Palazzo L, DAlessio F, Raia M, Improta S . The Fcp1-Wee1-Cdk1 axis affects spindle assembly checkpoint robustness and sensitivity to antimicrotubule cancer drugs. Cell Death Differ. 2015; 22(9):1551-60. PMC: 4532778. DOI: 10.1038/cdd.2015.13. View

12.

Morgan E, Arnold M, Gini A, Lorenzoni V, Cabasag C, Laversanne M . Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut. 2023; 72(2):338-344. DOI: 10.1136/gutjnl-2022-327736. View

13.

Cerrato A, Merolla F, Morra F, Celetti A . CCDC6: the identity of a protein known to be partner in fusion. Int J Cancer. 2017; 142(7):1300-1308. DOI: 10.1002/ijc.31106. View

14.

Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

15.

Cerrato A, Morra F, Celetti A . Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic. J Exp Clin Cancer Res. 2016; 35(1):179. PMC: 5123312. DOI: 10.1186/s13046-016-0456-2. View

16.

Hamatani K, Eguchi H, Koyama K, Mukai M, Nakachi K, Kusunoki Y . A novel RET rearrangement (ACBD5/RET) by pericentric inversion, inv(10)(p12.1;q11.2), in papillary thyroid cancer from an atomic bomb survivor exposed to high-dose radiation. Oncol Rep. 2014; 32(5):1809-14. DOI: 10.3892/or.2014.3449. View

17.

Soung Y, Lee J, Kim H, Park W, Kim S, Lee J . Inactivating mutations of CASPASE-7 gene in human cancers. Oncogene. 2003; 22(39):8048-52. DOI: 10.1038/sj.onc.1206727. View

18.

Morra F, Luise C, Visconti R, Staibano S, Merolla F, Ilardi G . New therapeutic perspectives in CCDC6 deficient lung cancer cells. Int J Cancer. 2014; 136(9):2146-57. DOI: 10.1002/ijc.29263. View

19.

Luise C, Merolla F, Leone V, Paladino S, Sarnataro D, Fusco A . Identification of sumoylation sites in CCDC6, the first identified RET partner gene in papillary thyroid carcinoma, uncovers a mode of regulating CCDC6 function on CREB1 transcriptional activity. PLoS One. 2012; 7(11):e49298. PMC: 3492267. DOI: 10.1371/journal.pone.0049298. View

20.

Hosoya N, Miyagawa K . Targeting DNA damage response in cancer therapy. Cancer Sci. 2014; 105(4):370-88. PMC: 4317796. DOI: 10.1111/cas.12366. View